Review Article

Management of Diabetic Gastroparesis

Badr M. Aljarallah

Department of Medicine, Gastroenterology Division, King Fahad Specialist Hospital, Faculty of Medicine, Qassim University, Maledia, Saudi Arabia

Address for correspondence:
Dr. Badr M. Aljarallah, Department of Medicine, Gastroenterology Division King Fahad Specialist Hospital, Faculty of Medicine, Qassim University, Maledia - 51452, Saudi Arabia. E-mail: bmj@qumedicine.org

ABSTRACT

Symptoms suggestive of gastroparesis occur in 5% to 12% of patients with diabetes. Such a complication can affect both prognosis and management of the diabetes; therefore, practicing clinicians are challenged by the complex management of such cases. Gastroparesis is a disorder characterized by a delay in gastric emptying after a meal in the absence of a mechanical gastric outlet obstruction. This article is an evidence-based overview of current management strategies for diabetic gastroparesis. The cardinal symptoms of diabetic gastroparesis are nausea and vomiting. Gastroesophageal scintiscanning at 15-minute intervals for 4 hours after food intake is considered the gold standard for measuring gastric emptying. Retention of more than 10% of the meal after 4 hours is considered an abnormal result, for which a multidisciplinary management approach is required. Treatment should be tailored according to the severity of gastroparesis, and 25% to 68% of symptoms are controlled by prokinetic agents. Commonly prescribed prokinetics include metoclopramide, domperidone, and erythromycin. In addition, gastric electrical stimulation has been shown to improve symptoms, reduce hospitalizations, reduce the need for nutritional support, and improve quality of life in several open-label studies.

Key Words: Diabetes, gastroparesis, vomiting, gastric emptying, insulin, glucose

Gastroparesis is a syndrome characterized by delayed gastric emptying in the absence of mechanical obstruction of the stomach in patients with diabetes.[1] The cardinal symptoms include postprandial fullness, nausea, vomiting, and bloating.[2,3]

Patients with diabetes in whom gastroparesis develops often have had diabetes for at least 10 years. Symptoms attributed to gastroparesis occur in almost 5% to 12% of patients with diabetes.[4-6] The data suggest that delayed gastric emptying and its symptoms are generally stable during 12 years of follow-up or more.[7] In a study of 86 patients with diabetes who were followed-up for at least 9 years, gastroparesis was not associated with mortality after 10 adjustments for other disorders.[8] Diabetic patients with gastroparesis have a normal life expectancy after adjustment for other disorders.

Access this article online	
Quick Response Code:	**Website:** www.saudijgastro.com
	DOI: 10.4103/1319-3767.77237

NORMAL GASTRIC EMPTYING

The proximal stomach serves as the reservoir for food, but also regulates the gastroduodenal flow rate and provides the space and time for pepsin and hydrochloric acid to initiate digestion.[9] Based on gastric barostat studies in human volunteers, over a liter of nutrients can be ingested without increased intragastric pressure.[10] Three main mechanisms involved in the regulation of the proximal stomach include the receptive relaxation reflex, the accommodation reflex, and enterogastric reflexes.[11] In the distal stomach, which acts as the grinder, there are 2 types of waves: the slow wave, controlled by the pacemaker cell (i.e., the interstitial cells of Cajal),[12] and phasic contractions, controlled by the migrating motor complex.[13] Neurohumoral factors play an essential role in the above mechanisms to control gastric motility.[14,15] The physical nature, particle size, fat, and caloric content of food determine its emptying rate. Solid nutrients usually empty in 2 phases over 3 to 4 hours.[16,17] An initial lag period (i.e., the retention phase) is followed by a propellant phase of relatively constant emptying. During the first phase, food gets churned[18] while antral contractions propel particles towards the closed pylorus. Foods are emptied once they have been broken down to particles of approximately 2 mm in diameter.

Liquid foods are usually emptied faster, especially in cases

of large volumes. If there are increased calories in the liquid, emptying is relatively constant over time.

Neurohumoral factors include glucose regulating hormones, which are released when food arrives in different regions of the gut and play an essential role in the above mechanisms to control both gastric motility and postprandial glycemia.[19]

GASTRIC EMPTYING AND ITS INFLUENCE ON BLOOD GLUCOSE AND INSULIN SECRETION

Nutrients empty from the stomach at an overall rate of about 2 to 3 kcal/min,[20] regulated predominantly by neural and hormonal feedback from the small intestine that further slows emptying by relaxing the fundus, suppressing antral and duodenal contractility, and stimulating tonic and phasic contractions.[21,22] Glucagon-like peptide-1 is one of the peptides involved in this feedback loop; others include glucose-dependent insulinotropic polypeptide, cholecystokinin, and peptide YY.[23] Although the rate of gastric emptying does not affect insulin secretion directly, it does regulate the delivery of carbohydrates and other macronutrients to the small intestine. This significantly impacts both the timing and magnitude of blood glucose excursion and peptide secretion, thereby modulating insulin release indirectly.

The effects of gastric emptying on both the peak and initial rise in blood glucose appear to be more direct than those of overall glycemia.[24] Similarly, the insulin requirement to sustain normoglycemia after a standard meal is substantially lower in type 1 diabetes patients with rather than without gastroparesis, the difference being apparent during the first 2 hours of the postprandial period.[25] Conversely, when gastric emptying is accelerated after ingestion of a meal with a smaller particle size in type 1 diabetes patients with gastroparesis, who are at risk for postprandial hypoglycemia, the postprandial blood glucose dip is diminished.[26]

In both healthy patients and type 2 diabetes patients, more rapid delivery of glucose to the small intestine does initially boost the peptide and insulin responses when compared with constant delivery of an identical glucose load. Nevertheless, this early increase in insulin cannot compensate for the greater initial rise in absorbed glucose, such that overall glycemic control is not improved.[27,28]

CLINICAL DIAGNOSIS

Nausea and vomiting are the cardinal symptoms of gastroparesis in patients with diabetes, occurring in 92% and 84% of affected patients, respectively, along with bloating (75%) and early satiety (60%).[29,30] Only the most severe gastroparesis results in daily vomiting. The symptoms of

gastroparesis also overlap with symptoms of metabolic disturbances, drug side effects, and other complications of diabetes (e.g., organic disorders, such as peptic ulcers, gastric and proximal small bowel obstruction, and biliary disease). Consequently, the diagnosis of gastroparesis is restricted to patients with chronic nausea and vomiting who have normal upper gastrointestinal imaging with objective evidence of profound delay in gastric emptying. Physical examination might be entirely normal, but in the most severe forms of gastroparesis dehydration and malnutrition might be present. Signs of associated systemic disease, such as systemic sclerosis, should be sought and particular care should be taken to ensure examination of the autonomic nervous system. An exaggerated postural drop both in systolic and diastolic blood pressure and on electrocardiogram might be a sign of autonomic neuropathy; vagal neuropathy is suspected if there is a loss of normal sinus dysrhythmia.[31]

Jones *et al.* concluded that the presence of abdominal bloating or fullness with no other upper gastrointestinal symptoms is associated with diabetic gastroparesis, and that gastric emptying is slower in diabetic women than in diabetic men.[32]

DIAGNOSTIC TESTING

The gold standard test to diagnose gastroparesis is scintigraphy. However, other techniques are also available, such as ultrasonography, ^{13}C breath testing, magnetic resonance imaging, swallowed capsule telemetry, antroduodenal manometry, and electrogastrography [Table 1].

Scintigraphy

In patients with suspected gastroparesis, ruling out obstruction is the first step, followed by determining the emptying time of the stomach. Scintiscanning at 15-minute intervals for 4 hours after food intake is considered the gold standard for measuring gastric emptying in detail. However, a simplified approach involving hourly scans to quantify residual gastric content is often used in practice.[19]

Table 1: Types of diagnostic modality	
Scintigraphy	Gold standard
[13]C breath test	Ideal alternative
Antroduodenal manometry	Distinguish between neuropathic and myopathic diseases
Electrogastrography	Focuses on the underlying myoelectrical activity
Swallowed capsule telemetry	Broadcasts in real time, intraluminal pH, phasic gastric pressure activity and ambient temperature
Magnetic resonance imaging	Measure gastric emptying and accommodation using sequential transaxial abdominal scans[104]

The approach usually employs technetium-99 m (99mTc) sulphur colloid, bound or added to a uniform test meal. The caloric and nutritional content of the test meal should be standardized.[33,34] Retention of more than 10% of the meal after 4 hours is considered abnormal.[35] Compared with the gold standard approach, the simplified approach has a specificity of 62% and a sensitivity of 93%.[36] However, as it provides the actual percentage of food emptied and requires fewer scans, the simplified approach is generally preferred. Further, scintiscanning requires special equipment and expertise, and involves exposure to radiation, providing further reasons why the simplified method might be preferable. Certain points are important to consider when interpreting the results—the emptying rate for women is longer than for men, a daily variation in emptying rate of up to 20% is expected, and standards differ among laboratories.

^{13}C breath test

Breath tests that measure gastric emptying involve ingestion of a meal enriched with a stable isotope, followed by the collection of breath samples; these are analyzed for carbon dioxide, using the isotope, at a reference laboratory. The profile of $^{13}CO_2$ excretion is used to estimate the half-time of gastric emptying.[37] Compared with detailed scintiscanning, the breath test has a specificity of 80% and a sensitivity of 86%.[38] However, three studies have shown that the test correlates well with scintigraphy.[39-41] Significant lung disease and small bowel maldigestion and malabsorption might influence the test, and patients with lung, small bowel, pancreatic, and liver diseases are considered unsuitable candidates.[31]

Antroduodenal manometry

Stationary or ambulatory antroduodenal manometry provides information on gastric and duodenal motor activity simultaneously. The information is helpful in building a full motor picture of the stomach and duodenum. Distinct patterns characterize the fasting and fed phases. Abnormal antroduodenal manometry has provided important information on the abnormalities occurring in diabetic gastroparesis, and it can distinguish between neuropathic and myopathic diseases. According to Mearin *et al.*, abnormal antroduodenal manometry results have revealed tonic and phasic pylorospasms, as well as abnormal patterns of small intestine contractions.[42]

Other screening measures

Other techniques are also available, such as electrogastrography, swallowed capsule telemetry, and magnetic resonance imaging. However, their roles in clinical practice still need to be further defined.

MANAGEMENT

Managing patients with diabetic gastroparesis requires a multidisciplinary approach, and usually involves gastroenterologists, dietitians, diabetologists, social workers, and diabetes educators. An important preemptive strategy is prevention, which can be attempted by controlling glucose levels; this has been proposed in many trials of acute hyperglycemia.[43-48] Although there is a lack of clinical trials showing that the restoration of euglycemia or correction of electrolyte derangement normalizes gastric emptying or ameliorates symptoms, clinical experience and observational data suggest that improved metabolic control is beneficial in the prevention of gastroparesis in patients with diabetes. Further preemptive strategies involve the prevention of other exacerbating factors, such as electrolyte disturbances and improving nutritional status.

Some dietary modifications are appropriate, but the expected clinical benefits are often modest. Alcohol and smoking delay gastric emptying and these habits should be discouraged. Fat delays emptying and nondigestible fiber (found in fresh fruits and vegetables) might be poorly emptied, as both require effective interdigestive antral motility that is frequently absent in diabetic gastroparesis patients. Patients should be advised to consume a low-fat diet (without nondigestible fiber) and to take frequent, small meals—dietitians play an essential role in providing professional advice and following up with those patients. In more severe cases, substitution of mixed meals with homogenized or liquid meals supplemented with vitamins and minerals is required. Enteral nutrition via a jejunostomy tube might occasionally be required, while parenteral nutrition should be restricted to patients with severe gastric and small intestine dysmotility for whom enteral feeding is nearly impossible.

Pharmacologic therapy

The aim of therapy is to improve the efficiency of the gastric pump and to relieve symptoms of nausea, bloating, vomiting, and pain. Selection of drugs is decided empirically. Two classes are available for treating affected patients, namely, prokinetic and antiemetic [Table 2].

Table 2: Management options	
Pharmacologic therapy	
Prokinetic agents	Little evidence from clinical trials to support the use of specific prokinetic regimens
Antiemetic agents	
Botulinum toxins	Restricted to clinical trials
Gastric electrical stimulation	Further studies are needed to define the best stimulation strategy and the mechanisms responsible for clinical improvement
Surgery	Insufficient data
Acupuncture	Insufficient data

Prokinetic agents

This class of drugs consists of the most commonly used medications for gastroparesis. Prokinetics stimulate peristalsis and might specifically improve gastric pump function by influencing antral contractility and rhythm as well as antroduodenal coordination.

Clinical trials have shown that compared with placebo these agents have increased gastric emptying by about 25%−72% and have reduced the severity of symptoms (typically measured with the use of Likert scales) by 25%−68%.[3,49-59] However, many of these trials were small, some were not blinded, some included patients with gastroparesis owing to causes other than diabetes, and many correlated poorly with influence on gastric emptying.[60,61]

Patterson and colleagues[53] conducted a double-blind, multicentre comparison of domperidone and metaclopramide for the treatment of patients with diabetes and concluded that each effectively reduced the symptoms of diabetic gastroparesis; however, central nervous system (CNS) side effects were more pronounced in patients taking metaclopramide. These side effects are believed to be more prevalent after long-term use, although data are conflicting and incomplete.[62-64]

One review looking at continuous use of metaclopramide showed insufficient evidence to conclude whether metaclopramide is efficacious for chronic use; routine monitoring might mitigate any risk associated with metaclopramide therapy.[65]

Domperidone is also widely used in this condition. Twenty-eight trials have assessed the efficacy of domperidone in diabetic gastroparesis, with a combined sample size of 1016 patients.[56,57,66-71] Overall, 64% of the studies showed significant improvement of symptoms with domperidone, 60% showed an efficacy in gastric emptying, and 67% proved the drug to be effective in reducing hospital admissions. These results need to be interpreted very cautiously, owing to the substantial methodological limitations of these studies. Unlike metaclopramide, domperidone does not cross the blood brain barrier; hence, there are no CNS side effects.

Cisapride, another prokinetic drug option, is associated with an increased risk of cardiac arrhythmia, including torsades de pointes, and is therefore currently withdrawn from the market and any future use requires special authorization.

Erythromycin is a motilin agonist that greatly increases the fractional rate of gastric emptying. Although a number of studies document the efficacy of erythromycin in improving gastric emptying, little information exists concerning symptom improvement in patients with diabetic gastroparesis. Thirty-five clinical trials[72] were conducted, and three studies[58,73,74] evaluated patients with diabetic gastroparesis (comprising a total number of 29 diabetic patients). None of the trials used symptoms as a primary end point, but instead studied different dose regimens and follow-up periods (e.g., 2 to 4 weeks). In one of these studies,[73] the average half-time of gastric emptying in diabetic subjects was 110 minutes (range 77 to 120) before treatment. The half-time decreased to an average of 55 minutes (range 29 to 15) after 3 weeks of treatment with erythromycin. Unlike in its oral form, intravenous erythromycin (3 mg/kg of body weight every 8 hours by infusion over 45 minutes) is more effective than placebo in relieving acute nondiabetic gastroparesis in hospitalized patients; however, no trials have included patients with diabetes or compared erythromycin with another agent.

Tegaserod is used in the treatment of women with constipation and predominant irritable bowel syndrome. The drug stimulates small intestine motility and, in healthy volunteers, there is evidence both for and against gastric prokinetic activity. The potential to influence gastric pump activity has been used to recommend its trial in gastroparesis, but currently there is no good evidence to support its use. Also, physicians require special authorization to prescribe tegaserod in clinical practice.

In summary, there is little evidence from clinical trials to support the use of specific prokinetic regimens in gastroparesis, but clinical experience suggests that a range of prokinetic drugs might be helpful in controlling nausea and vomiting. The choice of prokinetic is empirical, but it is common practice to initially prescribe metaclopramide (10 mg, 1 to 3 times daily) or domperidone (10 mg, 1 to 3 times daily). If both of these fail to control symptoms, erythromycin (250 mg, 3 times daily) should be the next option.

Antiemetic agents

Phenothiazines and antihistamines are commonly prescribed agents. Antiemetics are helpful in relieving vomiting. There are few clinical trials to support the use of specific agents. However, it is common practice to start patients with prochlorperazine and chlorpromazine; 5-hydroxytryptamine 3 receptor antagonists might be prescribed if these prove to be ineffective. In choosing which agents to use, availability and side effects should be considered.

Botulinum toxins

Botulinum toxins have been used in clinical trials on account of observational evidence of pylorospasms in manometric studies of patients with diabetes. *Pylorospasms* can be defined as prolonged periods of increased pyloric tone and phasic contractions. Botulinum toxins inhibit these contractions

100
Volume 17, Number 2
Rabi Al Thany 1432
March 2011

The Saudi Journal of
Gastroenterology

and have been proposed to improve symptoms. Data from a single-institution, randomized, double-blind, placebo-controlled trial[75] involving 16 patients with gastroparesis (only 9 of whom had diabetes) showed that botulinum toxin is not superior to placebo after 1 month of treatment. In concordance with those results, an earlier controlled trial also showed no efficacy.[76] However, four previous uncontrolled studies have suggested that endoscopic injections of botulinum toxins are efficacious.[77-80] One of the important points raised in the above studies is whether improvement of gastroparesis would necessarily improve the symptoms; the answer to that is not yet clear. Until a well-controlled study addressing botulinum toxin injections in patients with diabetic gastroparesis takes place, such a treatment should be restricted to clinical trials.

Gastric electrical stimulation

Gastric electrical stimulation (GES) involves the use of surgically placed electrodes in the muscle wall of the stomach cavity, about 9.5 to 10 cm from the pylorus along the greater curvature of the antrum.[81] The two electrodes are tangentially placed 1 cm apart deep in the muscularis propria, and are connected to a neurostimulator in a pocket of the abdominal wall. Intraoperative endoscopy is performed at the time of implantation to ensure that the leads are not accidentally pushed into the lumen of the stomach and are positioned appropriately in the muscularis propria of the stomach wall. The stimulator is set to generate high frequency (12 cycles per minute) low energy pulses (300 microsecond pulse width, 4 to 5 mA) for a short duration. In several open-label studies with mean follow-up periods of 3.7 to 4.3 years, short-pulse stimulation improved symptoms (in particular nausea and vomiting), reduced hospitalizations, reduced the need for nutritional support, and improved quality of life.[81-89] The first double-blind crossover trial[90] was published in 2003 and involved 33 patients with idiopathic or diabetic gastroparesis; each patient had 1 month on GES, 1 month off GES, and follow-up after 12 months. Patients included in the study had symptoms of gastroparesis for more than 1 year, were drug refractory, and had a vomiting frequency of more than 7 times per week. Overall, 79% of patients had a 55% decrease in vomiting only. Among the 17 patients in the study with diabetes, the median frequency of episodes of vomiting per week was 6.0 with the stimulator on and 12.8 with the stimulator off ($P=0.16$). In most of these studies, GES had no effect on gastric emptying; hence, the mechanism by which electrical stimulation improves symptoms is still unclear. GES has been proven to modulate the CNS in animal studies.[91] However, in a double-blind study from Denmark of 7 diabetes patients with medically refractory gastroparesis, no evidence was found for GES-induced modulation of the visceral sensory system and central excitability.[92]

Long-pulse GES has been reported to normalize slow-wave dysrhythmia and improve gastric emptying in patients with gastroparesis.[93] However, no implantable pulse generator is available to deliver long-pulse stimuli.

The most commonly seen complication has involved pacemakers, in which hardware infection has occurred requiring removal of the device.

Beyond clinical trials, there is insufficient sham-controlled evidence to support this therapy at the current time; further studies are needed to define the best stimulation strategy and the mechanisms responsible for clinical improvement.

Surgery

A systematic review[94] identified three uncontrolled studies[95-97] involving 32 patients using jejunostomy tubes with modest improvement of symptoms and nutrition intake. Also identified were three small case series[98-100] involving 6 patients who underwent pyloroplasty and gastrectomy, with minimal overall improvement. As such, the data for surgical treatment are insufficient to provide support for gastric surgical procedures in the treatment of patients with diabetic gastroparesis.

Acupuncture

Two studies assessed the effects of acupuncture in patients with diabetic gastroparesis.[101,102] In the study by Wang *et al*.,[101] individual acupuncture was superior to drug treatment (i.e., domperidone) with respect to symptoms, with a total efficacy rate of 94%. However, placebo control, blinding of patients or providers, statistical analyses, and calculations for effective rates were not described in the publication. In the uncontrolled study by Chang *et al*.,[102] cutaneous electrogastrography and serum parameters after needling of acupressure point ST-36 were assessed in 15 patients with diabetic gastroparesis. This experimental design revealed significant changes in electrogastrography and serum parameters after acupuncture, but presented no information about clinical effects.[103]

RECOMMENDATIONS

The purpose of this article is to increase awareness of diabetic gastroparesis and its complications for both physicians and patients. Recommendations based on the aforementioned findings are as follows:

- Any patient with diabetes who presents with recurrent nausea and vomiting should undergo scintigraphy to diagnose gastroparesis after first ruling out a gastric obstruction.
- Optimal blood sugar control, in consultation with a dietician, is a necessary first step.
- Treatment should be tailored according to the severity

Aljarallah

of gastroparesis, beginning with a combination of prokinetic and antiemetic drugs (metaclopramide, 10 mg 3 times daily before meals, and/either 10 mg prochlorperazine or 50 mg dimenhydrinate every 12 hours).

- If oral feeding is impossible, a trial of enteral feeding or parenteral feeding should be considered.

REFERENCES

1. Kassander P. Asymptomatic gastric retention in diabetics (gastroparesis diabeticorum). Ann Intern Med 1958;48:797-812.
2. Revicki DA, Rentz AM, Dubois D, Kahrilas P, Stanghellini V, Talley NJ, et al. Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Aliment Pharmacol Ther 2003;18:141-50.
3. Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association medical position statement: diagnosis and treatment of gastroparesis. Gastroenterology 2004;127:1589-91.
4. Enck P, Rathmann W, Spiekermann M, Czerner D, Tschöpe D, Ziegler D, et al. Prevalence of gastrointestinal symptoms in diabetic patients and non-diabetic subjects. Z Gastroenterol 1994;32:637-41.
5. Janatuinen E, Pikkarainen P, Laakso M, Pyörälä K. Gastrointestinal symptoms in middle-aged diabetic patients. Scand J Gastroenterol 1993;28:427-32.
6. Maleki D, Locke GR 3rd, Camilleri M, Zinsmeister AR, Yawn BP, Leibson C, et al. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med 2000;160:2808-16.
7. Jones KL, Russo A, Berry MK, Stevens JE, Wishart JM, Horowitz M. A longitudinal study of gastric emptying and upper gastrointestinal symptoms in patients with diabetes mellitus. Am J Med 2002;113:449-55.
8. Kong MF, Horowitz M, Jones KL, Wishart JM, Harding PE. Natural history of diabetic gastroparesis. Diabetes Care 1999;22:503-7.
9. Haans JJ, Masclee AA. Review article: The diagnosis and management of gastroparesis. Aliment Pharmacol Ther 2007;26:37-46.
10. Ahluwalia NK, Thompson DG, Barlow J. Effect of distension and feeding on phasic changes in human proximal gastric tone. Gut 1996;39:757-61.
11. Mizumoto A, Monchiki E, Suzuki H, Tanaka T, Itoh Z. Neuronal control of motility changes in the canine lower esophageal sphincter and stomach in response to meal ingestion. J Smooth Muscle Res 1997;33:211-22.
12. Hinder RA, Kelly K. Human gastric pacesetter potential. Site of origin, spread, and response to gastric transection and proximal gastric vagotomy. Am J Surg 1977;133:29-33.
13. Meyer JH, Ohashi H, Jehn D, Thomson JB. Size of liver particles emptied from the human stomach. Gastroenterology 1981;80:1489-96.
14. Morgan KG, Szurszewski JH. Mechanisms of phasic and tonic actions of pentagastrin on canine gastric smooth muscle. J Physiol 1980;30:229-42.
15. Hirst GD, Edwards FR. Role of interstitial cells of Cajal in the control of gastric motility. J Pharmacol Sci 2004;96:1-10.
16. Camilleri M. Integrated upper gastro-intestinal response to food intake. Gastroenterology 2006;131:640-58.
17. Hunt JN, Pathak JD .The osmotic effects of some simple molecules and ions on gastric emptying. J Physiol 1960;154:254-69.
18. Meyer JH, Ohashi H, Jehn D, Thomson JB. Size of liver particles emptied from the human stomach. Gastroenterology 1981;80:1489-96.
19. Camilleri M. Clinical practice. Diabetic gastroparesis. N Engl J Med 2007;356:820-9.
20. Ma J, Rayner CK, Jones KL, Horowitz M. Insulin secretion in healthy subjects and patients with Type 2 diabetes--role of the gastrointestinal tract. Best Pract Res Clin Endocrinol Metab 2009;23:413-24.
21. Schirra J, Houck P, Wank U, Arnold R, Göke B, Katschinski M. Effects of glucagon-like peptide-1 (7–36) amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut 2000;46:622–31.
22. Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, et al. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 2006;55:243-51.
23. MacIntosh CG, Andrews JM, Jones KL, Wishart JM, Morris HA, Jansen JB, et al. Effects of age on concentrations of plasma cholecystokinin, glucagon-like peptide 1, and peptide YY and their relation to appetite and pyloric motility. Am J Clin Nutr 1999;69:999-1006.
24. Gonlachanvit S, Hsu CW, Boden GH, Knight LC, Maurer AH, Fisher RS, et al. Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in type-II diabetic patients. Dig Dis Sci 2003;48:488-97.
25. Ishii M, Nakamura T, Kasai F, Onuma T, Baba T, Takebe K. Altered postprandial insulin requirement in IDDM patients with gastroparesis. Diabetes Care 1994;17:901-3.
26. Olausson EA, Alpsten M, Larsson A, Mattsson H, Andersson H, Attvall S. Small particle size of a solid meal increases gastric emptying and late postprandial glycaemic response in diabetic subjects with gastroparesis. Diabetes Res Clin Pract 2008;80:231-7.
27. O'Donovan DG, Doran S, Feinle-Bisset C, Jones KL, Meyer JH, Wishart JM, et al. Effect of variations in small intestinal glucose delivery on plasma glucose, insulin, and incretin hormones in healthy subjects and type 2 diabetes. J Clin Endocrinol Metab 2004;89:3431-5.
28. Chaikomin R, Doran S, Jones KL, Feinle-Bisset C, O'Donovan D, Rayner CK, et al. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects. Am J Physiol Endocrinol Metab 2005;289:E504-7.
29. Hasler WL. Gastroparesis--current concepts and considerations. Medscape J Med 2008;10:16.
30. Soykan I, Sivri B, Sarosiek I, Kiernan B, McCallum RW. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci 1998;43:2398-404.
31. Patrick A, Epstein O. Review article: gastroparesis. Aliment Pharmacol Ther 2008;27:724-40.
32. Jones KL, Russo A, Stevens JE, Wishart JM, Berry MK, Horowitz M. Predictors of delayed gastric emptying in diabetes. Diabetes Care 2001;24:1264-9.
33. Kim DY, Myung SJ, Camilleri M. Novel testing of human gastric motor and sensory functions: rationale, methods, and potential applications in clinical practice. Am J Gastroenterol 2000;95:3365-73.
34. Tougas G, Eaker EY, Abell TL, Abrahamsson H, Boivin M, Chen J, et al. Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol 2000;95:1456-62.
35. Tougas G, ChenY, Coates G, Paterson W, Dallaire C, Pare P, et al. Standardization of a simplified scintigraphic methodology for the assessment of gastric emptying in a multicenter setting. Am J Gastroenterol 2000;95:78-86.
36. Camilleri M, Zinsmeister AR, Greydanus MP, Brown ML, Proano M. Towards a less costly but accurate test of gastric emptying and small bowel transit. Dig Dis Sci 1991;36:609-15.
37. Choi MG, Burton DD, Zinsmeister AR, Forstrom LA, Nair KS. [13C] octanoic acid breath test for gastric emptying of solids: accuracy, reproducibility, and comparison with scintigraphy. Gastroenterology 1997;112:1155-62.
38. Choi MG, Camilleri M, Burton DD, Zinsmeister AR, Forstrom LA, Nair KS. Reproducibility and simplification of 13C-octanoic acid breath test

for gastric emptying of solids. Am J Gastroenterol 1998;93:92-8.

39. Ghoos YF, Maes BD, Geypens BJ, Mys G, Hiele MI, Rutgeerts PJ, et al. Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology 1993;104:1640-7.

40. Choi MG, Camilleri M, Burton DD, Zinsmeister AR, Forstrom LA, Nair KS. Reproducibility and simplification of 13C-octanoic acid breath test for gastric emptying of solids. Am J Gastroenterol 1998;93:92-8.

41. Bromer MQ, Kantor SB, Wagner DA, Knight LC, Maurer AH, Parkman HP. Simultaneous measurement of gastric emptying with a simple muffin meal using [13C]octanoate breath test and scintigraphy in normal subjects and patients with dyspeptic symptoms. Dig Dis Sci 2002;47:1657-63.

42. Mearin F, Camilleri M, Malagelada JR. Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology 1986;90:1919-25.

43. Fraser R, Horowitz M, Dent J. Hyperglycaemia stimulates pyloric motility in normal subjects. Gut 1991;32:475.

44. Barnett J, Owyang C. Serum glucose concentration as a modulator of interdigestive gastric motility. Gastroenterology 1988;94:739.

45. Fraser R, Horowitz M, Maddox AF, Harding PE, Chatterton BE, Dent J. Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990;33:675-80.

46. Jones K, Berry, M, Kong, MF. Hyperglycemia attenuates the gastrokinetic effect of erythromycin and affects the perception of postprandial hunger in normal subjects. Diabetes Care 1999;22:339.

47. Petrakis IE, Kogerakis N, Vrachassotakis N, Stiakakis I, Zacharioudakis G, Chalkiadakis G. Hyperglycemia attenuates erythromycin-induced acceleration of solid-phase gastric emptying in healthy subjects. Abdom Imaging 2002;27:309-14.

48. Horowitz M, Maddox AF, Wishart JM, Harding PE, Chatterton BE, Shearman DJ. Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus. Eur J Nucl Med 1991;18:229-34.

49. Abell TL, Bernstein RK, Cutts T, Farrugia G, Forster J, Hasler WL, et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil 2006;18:263-83.

50. Gaber AO, Oxley D, Karas J, Cardoso S, Hathaway D, Shokouh-Amiri MH, et al. Changes in gastric emptying in recipients of successful combined pancreas-kidney transplants. Dig Dis 1991;9:437-43.

51. Park MI, Camilleri M. Gastroparesis: clinical update. Am J Gastroenterol 2006;101:1129-39.

52. McCallum RW, Ricci DA, Rakatansky H, Behar J, Rhodes JB, Salen G, et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care 1983;6:463-7.

53. Patterson D, Abell T, Rothstein R, Koch K, Barnett J. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999;94:1230-4.

54. Dutta U, Padhy AK, Ahuja V, Sharma MP. Double blind controlled trial of effect of cisapride on gastric emptying in diabetics. Trop Gastroenterol 1999;20:116-9.

55. Braden B, Enghofer M, Schaub M, Usadel KH, Caspary WF, Lembcke B. Long-term cisapride treatment improves diabetic gastroparesis but not glycaemic control. Aliment Pharmacol Ther 2002;16:1341-6.

56. Soykan I, Sarosiek I, McCallum RW. The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis. Am J Gastroenterol 1997;92:976-80.

57. Silvers D, Kipnes M, Broadstone V, Patterson D, Quigley EM, McCallum R, et al. Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group. Clin Ther 1998;20:438-53.

58. Richards RD, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol 1993;88:203-7.

59. Franzese A, Borrelli O, Corrado G, Rea P, Di Nardo G, Grandinetti AL, et al. Domperidone is more effective than cisapride in children with diabetic gastroparesis. Aliment Pharmacol Ther 2002;16:951-7.

60. Thumshirn M, Camilleri M, Hanson RB, Williams DE, Schei AJ, Kammer PP. Gastric mechanosensory and lower esophageal sphincter function in rumination syndrome. Am J Physiol 1998;275:G314-21.

61. Ricci DA, Saltzman MB, Meyer C, Callachan C, McCallum RW. Effect of metoclopramide in diabetic gastroparesis. J Clin Gastroentero 1985;7:25-32.

62. Ganzini L, Heintz R, Hoffman WF, Casey DE. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study. Arch Gen Psychiatry 1991;48:259-63.

63. Shaffer D, Butterfield M, Pamer C, Mackey AC. Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride. J Am Pharm Assoc 2004;44:661-5.

64. Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug Insight: from disturbed motility to disordered movement - a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol 2006;3:138-48.

65. Lata PF, Pigarelli DL. Chronic metoclopramide therapy for diabetic gastroparesis. Ann Pharmacother 2003;37:122-6.

66. Barone JA. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother 1999;33:429-40.

67. Ahmad N, Keith-Ferris J, Gooden E, Abell T. Making a case for domperidone in the treatment of gastrointestinal motility disorders. Curr Opin Pharmacol 2006;6:571-6.

68. Miller M, Patterson DJ. Natural history of diabetic gastroparesis treated with cisapride or domperidone. Am J Gastroenterol 1991;86:1316.

69. Patterson DJ, BotomanVA, Kozarek RA, Skinner SM. Domperidone is effective long-term treatment for diabetic gastroparesis. Gastroenterology 1991;100:A137.

70. Cutts TF, Abell TL, Karas JG, Kuns J. Symptom improvement from prokinetic therapy corresponds to improved quality of life in patients with severe dyspepsia. Dig Dis Sci 1996;41:1369-78.

71. Shifflett J, McCallum RW. Long term efficacy, treatment outcome and quality of life in patients receiving chronic domperidone therapy for gastroparesis. Gastroenterology 1995;108:A35.

72. Maganti K, Onyemere K, Jones MP. Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol 2003;98:259-63.

73. Erbas T, Varoglu E, Erbas B, Tastekin G, Akalin S. Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Diabetes Care 1993;16:1511-4.

74. Samsom MJ, Akkermans LM. Effects of oral erythromycin on fasting and postprandial antroduodenal motility in patients with type I diabetes, measured with an ambulatory manometric technique. Diabetes Care 1997;20:129-34.

75. Friedenberg FK, Palit A, Parkman HP, Hanlon A, Nelson DB. Botulinum toxin A for the treatment of delayed gastric emptying. Am J Gastroenterol 2008;103:416-23.

76. Arts J, Holvoet L, Caenepeel P, Bisschops R, Sifrim D, Verbeke K, et al. Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment Pharmacol Ther 2007;26:1251-8.

77. Ezzeddine D, Jit R, Katz N, Gopalswamy N, Bhutani MS. Pyloric injection of botulinum toxin for treatment of diabetic gastroparesis. Gastrointest Endosc 2002;55:920-3.

78. Lacy BE, Crowell MD, Schettler-Duncan A, Mathis C, Pasricha PJ. The treatment of diabetic gastroparesis with botulinum toxin injection of the pylorus. Diabetes Care 2004;27:2341-7.

79. Bromer MQ, Friedenberg F, Miller LS, Fisher RS, Swartz K, Parkman HP. Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis. Gastrointest Endosc 2005;61:833-9.

80. Arts J, van Gool S, Caenepeel P, Verbeke K, Janssens J, Tack J. Influence of intrapyloric botulinum toxin injection on gastric emptying and meal-related symptoms in gastroparesis patients. Aliment Pharmacol Ther 2006;24:661-7.

81. Yin J, Chen JD. Implantable gastric electrical stimulation: Ready for prime time? Gastroenterology 2008;134:665-7.

82. Familoni BO, Abell TL, Bhaskar SK, Voeller GR, Blair SR. Gastric electrical stimulation has an immediate antiemetic effect in patients with gastroparesis. IEEE Trans Biomed Eng 2006;53:1038-46.

83. Familoni BO, Abell TL, Voeller G, Salem A, Gaber O. Electrical stimulation at a frequency higher than basal rate in human stomach. Dig Dis Sci 1997;42:885-91.

84. De Csepel J, Goldfarb B, Shapsis A, Goff S, Gabriel N, Eng HM. Electrical stimulation for gastroparesis. Gastric motility restored. Surg Endosc 2006;20:302-6.

85. Lin Z, Sarosiek I, Forster J, McCallum RW. Symptom responses, long-term outcomes and adverse events beyond 3 years of high-frequency gastric electrical stimulation for gastroparesis. Neurogastroenterol Motil 2006;18:18-27.

86. Mason RJ, Lipham J, Eckerling G, Schwartz A, Demeester TR. Gastric electrical stimulation: an alternative surgical therapy for patients with gastroparesis. Arch Surg 2005;140:841-6.

87. McCallum R, Lin Z, Wetzel P, Sarosiek I, Forster J. Clinical response to gastric electrical stimulation in patients with postsurgical gastroparesis. Clin Gastroenterol Hepatol 2005;3:49-54.

88. Lin Z, Forster J, Sarosiek I, McCallum RW. Treatment of diabetic gastroparesis by high-frequency gastric electrical stimulation. Diabetes Care 2004;27:1071-6.

89. Abell TL, Van Cutsem E, Abrahamsson H, Huizinga JD, Konturek JW, Galmiche JP, et al. Gastric electrical stimulation in intractable symptomatic gastroparesis. Digestion 2002;66:204-12.

90. Abell T, McCallum R, Hocking M, Koch K, Abrahamsson H, Leblanc I, et al. Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology 2003;125:421-8.

91. Chen JD, Qian L, Ouyang H, Yin J. Gastric electrical stimulation with short pulses reduces vomiting but not dysrhythmia in dogs. Gastroenterology 2003;124:401-9.

92. Frokaejr JB, Ejskjaer N, Rask P, Andersen SD, Gregersen H, Drewes AM. Central neuronal mechanisms of gastric electrical stimulation in diabetic gastroparesis. Scand J Gastroenterol 2008;43:1066-75.

93. McCallum RW, Chen JD, Lin Z, Schirmer BD, Williams RD, Ross RA. Gastric pacing improves emptying and symptoms in patients with gastroparesis. Gastroenterology 1998;114:456-61.

94. Michael P, Jones KM. A systematic review of surgical therapy for gastroparesis. Am J Gastroenterol 2003;98:2122-9.

95. Devendra D, Millward BA, Travis SP. Diabetic gastroparesis improved by percutaneous endoscopic jejunostomy. Diabetes Care 2000;23:426-7.

96. Jacober SJ, Narayan A, Strodel WE, Vinik AI. Jejunostomy feeding in the management of gastroparesis diabeticorum. Diabetes Care 1986;9:217-9.

97. Fontana RJ, Barnett JL. Jejunostomy tube placement in refractory diabetic gastroparesis: a retrospective review. Am J Gastroenterol 1996;91:2174-8.

98. Wooten RL, Meriwether TW. Diabetic gastric atony: a clinical study. JAMA 1961;176:1082-7.

99. Roon AJ, Mason GR. Surgical management of gastroparesis diabeticorum. Calif Med 1972;116:58-61.

100. Shellito PC, Warshaw AL. Idiopathic intermittent gastroparesis and its surgical alleviation. Am J Surg 1984;148:408-12.

101. Wang L. Clinical observation on acupuncture treatment in 35 cases of diabetic gastroparesis. J Tradit Chin Med 2004;24:163-5.

102. Chang CS, Ko CW, Wu CY, Chen GH. Effect of electrical stimulation on acupuncture points in diabetic patients with gastric dysrhythmia: a pilot study. Digestion 2001;64:184-90.

103. Schneider A, Streitberger K, Joos S. Acupuncture treatment in gastrointestinal diseases: a systematic review. World J Gastroenterol 2007;13:3417-24.

104. Kim DY, Myung SJ, Camilleri M. Novel testing of human gastric motor and sensory functions: rationale, methods, and potential applications in clinical practice. Am J Gastroenterol 2000;95:3365-73.

104
Volume 17, Number 2
Rabi Al Thany 1432
March 2011

The Saudi Journal of
Gastroenterology